Early identification and treatment of sepsis are essential to combat one of the leading causes of hospital patient deaths.1 With 43 targets, the newly expanded and FDA-cleared BioFire® Blood Culture Identification 2 (BCID2) Panel detects pathogens and antimicrobial resistance genes directly from positive blood cultures.
The BioFire BCID2 Panel tests for 43 targets associated with bloodstream infections, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes—all with one test and with results available in about an hour from positive blood culture.
The BioFire BCID2 Panel features broadened inclusivity for Enterobacterales, new assays for fungal and anaerobic pathogens, and additional identification of coagulase-negative Staphylococcus species. The BioFire BCID2 Panel menu includes seven additional resistance genes, including carbapenemases and colistin resistance genes. An MREJ assay allows for more specific MRSA identification.
Overall 99% Sensitivity and 99.8% Specificity2
Sample Type: Positive blood culture
GRAM-NEGATIVE BACTERIA:
GRAM-POSITIVE BACTERIA:
YEAST:
ANTIMICROBIAL RESISTANCE GENES:
The IDSA recommends the addition of rapid diagnostic testing to an effective Antimicrobial Stewardship Program.3 A study at the Mayo Clinic shows that pairing the BioFire® FilmArray® Blood Culture Identification (BCID) Panel with antimicrobial stewardship provides the greatest benefit.4
Adapted from Banerjee R, et al. Clinical Infectious Diseases 2015;61(7):1
The BioFire BCID Panel and antimicrobial stewardship interventions decreased time to optimal therapy by 33.5 hours.1
Faster organism identification and reduced time to optimal therapy can also lead to better economic outcomes. BioFire BCID Panel identification of coagulase-negative staphylococci contaminants resulted in shorter post-culture length of stay and saved roughly $30,000 per 100 patients tested.5
The BioFire BCID Panel, combined with antimicrobial stewardship, achieved >$3,000 per patient in overall hospital savings5**
** Outcomes from patients with blood cultures growing gram-positive cocci and Candida.
– Medical University of South Carolina
Charleston, SC
The original BioFire BCID Panel delivers results on 24 targets, including gram-positive, gram-negative, and yeast pathogens, as well as 3 antimicrobial resistance genes associated with bloodstream infections.
To order the BioFire BCID2 Panel, contact your regional sales representative or use the following contact information:
| Product Name | Part Number | Quantity |
|---|---|---|
| BioFire BCID Panel Reagents | RFIT-ASY-0127 | 6-Pack |
| BioFire BCID Panel Reagents | RFIT-ASY-0126 | 30-Pack |
| BioFire BCID2 Panel Reagents | RFIT-ASY-0147 | 30-Pack |
Syndromic infectious disease diagnostics from BioFire can help take the guesswork out of pathogen identification. Syndromic testing combines several potential targets into one rapid in vitro diagnostic test. Fast sample-to-answer turnaround combined with comprehensive menus helps inform timely optimal therapy.
Learn more about syndromic infectious disease testing from BioFire
Pneumonia
Respiratory
Gastrointestinal
Meningitis
Joint Infection
Product availability varies by country. Consult your bioMérieux representative.
References: